Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGP57380 is a selective, small molecule inhibitor of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1), with reported inhibitory activity against MNK2 as well. It is a pyrazolopyrimidine derivative with a 4-fluorophenyl group. CGP57380 inhibits MNK1-mediated phosphorylation of eIF4E, which downregulates translation of mRNAs involved in oncogenesis and cell survival, such as Mcl-1, Bcl-2, c-Myc, and cyclin D1. In preclinical studies, it has demonstrated ability to induce apoptosis and suppress tumor growth in models of T-cell acute lymphoblastic leukemia, non-small cell lung cancer, and other cancer cell lines, particularly when used in combination with other agents targeting the mTOR pathway[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CGP57380.